We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Ultra-Rapid Sepsis Test Enables Immediate Clinical Decision-Making at Fingertips

By LabMedica International staff writers
Posted on 12 Aug 2022
Print article
Image: Predictive ultra-rapid sepsis test enables management of antibiotic administration (Photo courtesy of Abionic SA)
Image: Predictive ultra-rapid sepsis test enables management of antibiotic administration (Photo courtesy of Abionic SA)

Sepsis, one of the leading causes of death worldwide, is a life-threatening condition caused by a dysregulated host response to infection, which can progress to multiple organ dysfunction, septic shock and even death. Sepsis early warning signs and symptoms, such as fever, chills, nausea, fatigue, pain, etc., are generic and non-specific, making it extremely challenging to differentiate sepsis from other conditions. However, research shows that the early detection of sepsis with timely, appropriate interventions increases the likelihood of survival. Pancreatic Stone Protein (PSP) is a protein biomarker produced by the pancreas and secreted in response to sepsis-related organ dysfunction. PSP has shown great accuracy as an early warning sign of sepsis, increasing up to three days before overt clinical signs and symptoms appear. Now, an ultra-rapid nanofluidic-based diagnostic platform and the PSP biomarker have been brought together to offer a unique bedside test for the earliest and immediate detection of sepsis.

Abionic SA’s (Lausanne, Switzerland) PSP sepsis diagnosis test on the company’s abioSCOPE device allows for identification of the biomarker up to 72 hours before the standard of care in five minutes. Abionic’s nanotechnology is transforming today’s blood-testing standards by bringing laboratory quality to near-patient testing and simultaneously analyzing up to 14 parameters from a single drop of blood, to provide actionable results in just five minutes. By driving molecules into a nanochannel and limiting the travel distance to a few hundred nanometres, molecular interactions are accelerated rapidly. Thus, biomarker levels of e.g. antibodies and proteins can be efficiently quantified within an extremely short assay time, with high precision and accuracy on a closed, small and easy-to-operate platform.

Abionic’s newly IVDR certified PSP test is particularly useful for guiding physicians in the decision to start or modify antibiotic treatment. Antibiotics are medicines that are used to prevent and treat bacterial infections, although their systematic overuse and misuse is leading to a concerning increase in the number of antibiotic resistant bacteria, which are becoming harder to treat and causing more severe and fatal infections. Aside from contributing to resistance, inappropriate antibiotic use may lead to increased mortality and severe disease, increased healthcare costs, increased lengths of stay in hospital and the need for more complex treatments leading to a higher risk for adverse effects and unwanted drug interactions. Abionic’s PSP test can help physicians decide whether or not to begin antibiotic therapy, and thereby contribute to reducing the two major public health problems of sepsis and antimicrobial resistance.

Related Links:
Abionic SA 

New
Gold Supplier
Real-Time PCR System
STC-96A Plus
New
Data Management Software
DataSite
New
Automated Immunoassay Analyzer
cobas e 411
New
Rapid Procalcitonin (PCT) Test
AQT90 FLEX PCT Assay

Print article
IIR Middle East

Channels

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.